Coya Therapeutics (NASDAQ:COYA) Announces Earnings Results

Coya Therapeutics (NASDAQ:COYA) issued its quarterly earnings results on Monday. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.26), FiscalAI reports. Coya Therapeutics had a negative return on equity of 55.76% and a negative net margin of 462.24%.The business had revenue of $3.96 million during the quarter, compared to analysts’ expectations of $1.93 million.

Coya Therapeutics Stock Down 0.7%

Coya Therapeutics stock opened at $4.50 on Tuesday. The company’s 50-day moving average price is $4.75 and its 200-day moving average price is $5.58. The company has a market cap of $94.14 million, a PE ratio of -4.05 and a beta of 0.23. Coya Therapeutics has a twelve month low of $3.94 and a twelve month high of $7.75.

Wall Street Analysts Forecast Growth

COYA has been the subject of several research analyst reports. Chardan Capital reiterated a “buy” rating and set a $14.00 target price on shares of Coya Therapeutics in a research report on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, January 21st. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Coya Therapeutics in a report on Monday, February 2nd. Finally, D. Boral Capital reiterated a “buy” rating and set a $15.00 price objective on shares of Coya Therapeutics in a research report on Monday. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $16.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Alyeska Investment Group L.P. purchased a new stake in Coya Therapeutics during the fourth quarter valued at approximately $4,640,000. AWM Investment Company Inc. bought a new stake in shares of Coya Therapeutics in the 4th quarter valued at approximately $4,205,000. Private Management Group Inc. purchased a new position in shares of Coya Therapeutics in the 4th quarter worth approximately $1,626,000. Marshall Wace LLP boosted its holdings in shares of Coya Therapeutics by 438.8% in the 4th quarter. Marshall Wace LLP now owns 225,358 shares of the company’s stock worth $1,307,000 after purchasing an additional 183,533 shares during the period. Finally, Geode Capital Management LLC increased its position in shares of Coya Therapeutics by 26.2% during the 4th quarter. Geode Capital Management LLC now owns 197,988 shares of the company’s stock valued at $1,149,000 after purchasing an additional 41,143 shares during the last quarter. Hedge funds and other institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.